Kurzfassung

A 64-week, two-arm, randomized, double-masked, multicenter,
phase IIIb study assessing the efficacy and safety
of brolucizumab 6 mg compared to aflibercept 2 mg in a
treat-to-control regimen in patients with neovascular agerelated
macular degeneration